Cargando…

Low CCL19 expression is associated with adverse clinical outcomes for follicular lymphoma patients treated with chemoimmunotherapy

BACKGROUND: This study aimed to recognize the hub genes associated with prognosis in follicular lymphoma (FL) treated with first-line rituximab combined with chemotherapy. METHOD: RNA sequencing data of dataset GSE65135 (n = 24) were included in differentially expressed genes (DEGs) analysis. Weight...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Yu, Wang, Shasha, Tao, Yunxia, Chen, Haizhu, Qin, Yan, He, Xiaohui, Zhou, Shengyu, Liu, Peng, Yang, Jianliang, Yang, Sheng, Gui, Lin, Lou, Ning, Zhang, Zhishang, Yao, Jiarui, Han, Xiaohong, Shi, Yuankai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454033/ https://www.ncbi.nlm.nih.gov/pubmed/34544443 http://dx.doi.org/10.1186/s12967-021-03078-9

Ejemplares similares

Recombinant human thrombopoietin prior to mobilization chemotherapy facilitates platelet recovery in autologous transplantation in patients with lymphoma: Results of a prospective randomized study
por: Mo, Hongnan, et al.
Publicado: (2021)

Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP
por: Qin, Yan, et al.
Publicado: (2022)

Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era
por: Chen, Haizhu, et al.
Publicado: (2022)

Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin’s lymphoma
por: Shi, Yuankai, et al.
Publicado: (2015)

Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy
por: Han, Xiaohong, et al.
Publicado: (2019)

Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma
por: Merryman, Reid W., et al.
Publicado: (2023)

Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma
por: Huang, Yu, et al.
Publicado: (2017)

Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era
por: Correia, Cristina, et al.
Publicado: (2023)

Minimal Residual Disease and Survival Outcomes in Patients with Mantle Cell Lymphoma: a systematic review and meta-analysis
por: Zhou, Yu, et al.
Publicado: (2021)

Prognostic Nomogram and Predictive Factors in Refractory or Relapsed Diffuse Large B-Cell Lymphoma Patients Failing Front-Line R-CHOP Regimens
por: Jiang, Shiyu, et al.
Publicado: (2020)

Proteomics Identifies Circulating TIMP-1 as a Prognostic Biomarker for Diffuse Large B-Cell Lymphoma
por: Lou, Ning, et al.
Publicado: (2023)

Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era
por: Wang, Qin, et al.
Publicado: (2016)

The changing landscape of anti-lymphoma drug clinical trials in mainland China in the past 15 years (2005–2020): A systematic review
por: Chen, Haizhu, et al.
Publicado: (2021)

Skeletal Muscle Radio-Density Is an Independent Predictor of Response and Outcomes in Follicular Lymphoma Treated with Chemoimmunotherapy
por: Chu, Michael P., et al.
Publicado: (2015)

Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma
por: Zhu, Yunshu, et al.
Publicado: (2020)

Characteristics and Management of TP53-Mutated Diffuse Large B-Cell Lymphoma Patients
por: Qin, Yan, et al.
Publicado: (2020)

Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma
por: Gui, Lin, et al.
Publicado: (2016)

MYD88(L265P) and MYD88(other) variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma
por: Qin, Yan, et al.
Publicado: (2023)

Development of new prognostic model based on pretreatment βLRI and LLRI for stage IE/IIE upper aerodigestive tract ENKTL, nasal type
por: Dai, Wumin, et al.
Publicado: (2017)

Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients
por: Tan, Qiaoyun, et al.
Publicado: (2020)

The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020
por: Zhong, Qiaofeng, et al.
Publicado: (2021)

Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China
por: Shi, Yuankai, et al.
Publicado: (2019)

Frontline treatment with chemoimmunotherapy for limited-stage ocular adnexal MALT lymphoma with adverse factors: a phase II study
por: Kim, Sung-Yong, et al.
Publicado: (2017)

P1095: COVID-19 VACCINE RESPONSES IN FOLLICULAR LYMPHOMA: DETERMINANTS OF HUMORAL AND CELLULAR IMMUNITY IN THE PETREA TRIAL OF FRONTLINE CHEMOIMMUNOTHERAPY
por: Jer Lim, Yeong, et al.
Publicado: (2023)

Follicular thyroid carcinoma but not adenoma recruits tumor-associated macrophages by releasing CCL15
por: Huang, Feng-Jiao, et al.
Publicado: (2016)

Trends of Phase I Clinical Trials of New Drugs in Mainland China Over the Past 10 Years (2011–2020)
por: Chen, Chen, et al.
Publicado: (2021)

Antibody response to SARS-CoV-2 WT and Omicron BA.4/5 of inactivated COVID-19 vaccine in patients with lung cancer after second and booster immunization
por: Chen, Chen, et al.
Publicado: (2023)

Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy
por: Yuen, Hiu Lam Agnes, et al.
Publicado: (2020)

Delayed COVID-19 Respiratory Failure in Patients with Lymphoma on Rituximab-based Chemoimmunotherapy
por: Hoffmann, Marc S., et al.
Publicado: (2021)

R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma
por: Lee, Hong Ghi, et al.
Publicado: (2014)

Follicular Lymphoma
por: Yavaşoğlu, İrfan
Publicado: (2015)

Follicular lymphoma
por: Leich, Ellen
Publicado: (2019)

Efficacy and safety of immune checkpoint inhibitor rechallenge in non‐small cell lung cancer: A systematic review and meta‐analysis
por: Feng, Yu, et al.
Publicado: (2023)

Targeted delivery of liposomal chemoimmunotherapy for cancer treatment
por: Liu, Yusheng, et al.
Publicado: (2022)

A rare face of follicular lymphoma: reverse variant of follicular lymphoma
por: Maskey, Ninu, et al.
Publicado: (2020)

Follicular Lymphoma in China: Systematic Evaluation of Follicular Lymphoma Prognostic Models
por: Li, Yanan, et al.
Publicado: (2022)

Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma
por: Kambhampati, Swetha, et al.
Publicado: (2022)

MAPK signaling regulates the efficacy of chemoimmunotherapy
por: Ghiringhelli, François
Publicado: (2022)

Screening of Adverse Prognostic Factors and Construction of Prognostic Index in Previously Untreated Concurrent Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
por: Qu, Zhenjie, et al.
Publicado: (2022)

Follicular Lymphoma Presenting as Intussusception in an Adult
por: Haq, Muhammad S, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fm10ue43tokl15bc2tvcpc7vqv